Brought to you by 
RTI Biologics gets rights to Athersys' stem cell IP
24 Feb 2023
Executive Summary
Cell therapy company Athersys Inc. has licensed RTI Biologics Inc. (biological implants) rights to use its Multipotent Adult Progenitor Cell (MAPC) technologies to develop orthopedic implants.
Deal Industry
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RTI Biologics gets rights to Athersys' stem cell IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice